These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 34339089)

  • 21. Factors Influencing Allopurinol Initiation in Primary Care.
    Clarson LE; Hider SL; Belcher J; Roddy E; Mallen CD
    Ann Fam Med; 2017 Nov; 15(6):557-560. PubMed ID: 29133496
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of an adherence-enhancing intervention for gout based on real-world data.
    Lin LW; Teng GG; Lim AYN; Yoong JS; Zethraeus N; Wee HL
    Int J Rheum Dis; 2019 Apr; 22(4):545-554. PubMed ID: 30556300
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quality of care for gout in the US needs improvement.
    Singh JA; Hodges JS; Toscano JP; Asch SM
    Arthritis Rheum; 2007 Jun; 57(5):822-9. PubMed ID: 17530682
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Education Preferences of People With Gout: Exploring Differences Between Indigenous and Nonindigenous Peoples from Rural and Urban Locations.
    Treharne GJ; Richardson AC; Neha T; Fanning N; Janes R; Hudson B; Judd A; Pitama S; Stamp LK
    Arthritis Care Res (Hoboken); 2018 Feb; 70(2):260-267. PubMed ID: 28464485
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gout in Aotearoa New Zealand: the equity crisis continues in plain sight.
    Dalbeth N; Dowell T; Gerard C; Gow P; Jackson G; Shuker C; Te Karu L
    N Z Med J; 2018 Nov; 131(1485):8-12. PubMed ID: 30408813
    [No Abstract]   [Full Text] [Related]  

  • 26. Adherence and persistence to urate-lowering therapies in the Irish setting.
    McGowan B; Bennett K; Silke C; Whelan B
    Clin Rheumatol; 2016 Mar; 35(3):715-21. PubMed ID: 25409858
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rising Incidence of Acute Hospital Admissions due to Gout.
    Russell MD; Yates M; Bechman K; Rutherford AI; Subesinghe S; Lanyon P; Galloway JB
    J Rheumatol; 2020 Apr; 47(4):619-623. PubMed ID: 31523046
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modifiable factors associated with allopurinol adherence and outcomes among patients with gout in an integrated healthcare system.
    Rashid N; Coburn BW; Wu YL; Cheetham TC; Curtis JR; Saag KG; Mikuls TR
    J Rheumatol; 2015 Mar; 42(3):504-12. PubMed ID: 25512479
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of Gout in a Hospital Setting: A Lost Opportunity.
    Wright S; Chapman PT; Frampton C; O'Donnell JL; Raja R; Stamp LK
    J Rheumatol; 2017 Oct; 44(10):1493-1498. PubMed ID: 28765252
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rates of adherence and persistence with allopurinol therapy among gout patients in Israel.
    Zandman-Goddard G; Amital H; Shamrayevsky N; Raz R; Shalev V; Chodick G
    Rheumatology (Oxford); 2013 Jun; 52(6):1126-31. PubMed ID: 23392592
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum urate levels and therapy in adults treated with long-term dialysis: a retrospective cross-sectional study.
    Yeo E; Palmer SC; Chapman PT; Frampton C; Stamp LK
    Intern Med J; 2019 Jul; 49(7):838-842. PubMed ID: 30426652
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The challenges of managing gout in primary care: Results of a best-practice audit.
    Stamp LK; Chapman P; Hudson B; Frampton C; Hamilton G; Judd A
    Aust J Gen Pract; 2019 Sep; 48(9):631-637. PubMed ID: 31476837
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Does starting allopurinol prolong acute treated gout? A randomized clinical trial.
    Hill EM; Sky K; Sit M; Collamer A; Higgs J
    J Clin Rheumatol; 2015 Apr; 21(3):120-5. PubMed ID: 25807090
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
    Chohan S; Becker MA; MacDonald PA; Chefo S; Jackson RL
    Arthritis Care Res (Hoboken); 2012 Feb; 64(2):256-61. PubMed ID: 22052584
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Allopurinol Medication Adherence as a Mediator of Optimal Outcomes in Gout Management.
    Coburn BW; Bendlin KA; Sayles H; Meza J; Russell CL; Mikuls TR
    J Clin Rheumatol; 2017 Sep; 23(6):317-323. PubMed ID: 28816767
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quality use of allopurinol in the elderly.
    Smith P; Karlson N; Nair BR
    J Qual Clin Pract; 2000 Mar; 20(1):42-3. PubMed ID: 10821456
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiovascular Risks of Probenecid Versus Allopurinol in Older Patients With Gout.
    Kim SC; Neogi T; Kang EH; Liu J; Desai RJ; Zhang M; Solomon DH
    J Am Coll Cardiol; 2018 Mar; 71(9):994-1004. PubMed ID: 29496000
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of sequential urate lowering therapies for the management of gout in Singapore.
    Pruis SL; Jeon YK; Pearce F; Thong BY; Aziz MIA
    J Med Econ; 2020 Aug; 23(8):838-847. PubMed ID: 32301360
    [No Abstract]   [Full Text] [Related]  

  • 39. Debunking the myths to provide 21st Century management of gout.
    Winnard D; Kake T; Gow P; Barratt-Boyes C; Harris V; Hall DA; Mason H; Merriman T; Dalbeth N;
    N Z Med J; 2008 May; 121(1274):79-85. PubMed ID: 18535649
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [A model-based meta-analysis to compare urate-lowering response rate of febuxostat and allopurinol in gout patient].
    Sun Y; Li L; Zhou TY; Lu W
    Yao Xue Xue Bao; 2014 Dec; 49(12):1674-83. PubMed ID: 25920196
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.